Startup
Victorian biotechnology company developing new treatments for polycystic kidney disease
Programs: Brandon BioCatalyst (CUREator)
Every investor coverage indicates participated in a round xCystence Bio raised.
| Investor | Rounds | Invested |
|---|---|---|
| BioCurate | Pre-seed | - |
| Brandon BioCatalyst | Accelerator | - |
| Breakthrough Victoria | Pre-seed | - |
| Monash Ventures Pre-Seed Fund | Pre-seed | - |
| Uniseed | Pre-seed | - |
Companies xCystence Bio acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Ian Smyth | Co-founder and Biology Lead | - |
| Paul Stupple | Co-founder and Chemistry Lead | - |
Stories naming xCystence Bio. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
xCystence Bio secured pre-seed funding from Uniseed, Monash Ventures, Breakthrough Victoria, and BioCurate to develop targeted protein degraders for treating genetic kidney disease.
Breakthrough Victoria reports investing in xCystence Bio, a Monash University spinout developing polycystic kidney disease therapies, via its University Innovation Platform alongside BioCurate and UniSeed.
Also Uniseed
Biotech incubator CUREator's second round distributes $12 million among 19 health-focused startups, supported by government funding, while a new MedTech program backed by $50 million arrives later in the year.
CUREator, the national biotech incubator operated by Brandon BioCatalyst, selects 19 projects for its second funding round worth $12 million, and a $50 million MRFF award will add a MedTech stream.